Announcement PDF Company Announcement IMAGION BIOSYSTEMS LIMITED ASX: IBX 14 June 2024 Appendix 3Y Cover Note MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, makes this announcement in relation to the Appendix 3Y “Change of Director’s Interest Notice” for Robert Proulx, Mark VanAsten, Michael Harsh and David Ludvigson following the share consolidation as approved at the Company’s Extraordinary General Meeting on 13 November 2023. The Company advises the following in relation to the late lodgement of these documents: • The Appendix 3Ys are being lodged late due to an administrative oversight. As soon as the oversight was identified, the documents were prepared and lodged with the ASX. • The Company and its Directors are aware of their obligations under Listing Rules 3.19A and 3.19B and have procedures in place in accordance with the Company’s Continuous Disclosure Policy to meet its disclosure obligations. • The Company considers that the late lodgement is an isolated incident and believes its current practices are adequate to ensure compliance with the Listing Rules. ⎯ ENDS ⎯ About Imagion Biosystems Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASXlisted company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company’s lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems’ MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs. For more information, visit https://imagionbiosystems.com/investor-hub/ Authorisation & Additional information This announcement was authorised by the Board of Imagion Biosystems Limited.